Editorial Policy
How the Remy Peptides editorial team sources evidence, reviews copy, logs corrections, and applies For Research Use Only guardrails across the library.
Editorial Workflow
Every article goes through four steps before publication, with the source file, publication date, and last-reviewed date checked before sign-off:
- Drafting — a subject-matter expert writes the article using only primary and peer-reviewed sources.
- Internal review — a second reviewer cross-checks every numerical claim against the cited document.
- Editorial sign-off — the editorial team verifies scientific accuracy, regulatory-status accuracy, compliance wording, and consistency with the rest of the library.
- Post-publication monitoring — articles are re-reviewed when new clinical data, regulatory decisions, broken citations, or reader reports trigger an update.
For source hierarchy and what we will not cite, see research standards. Approval trackers and regulatory-status pages are prioritized for refresh immediately after a primary-source event; evergreen explainers, dosage guides, and comparison pages are re-reviewed on a rolling quarterly cadence or sooner when material new data appears.
Editorial Leadership
The team holds backgrounds in pharmaceutical sciences, biochemistry and HPLC analytical chemistry, and clinical research methodology (Phase 2/3 trial design, biostatistics, regulatory filings). Long-form pages credit the Remy Peptides Editorial Team or the Remy Peptides Editorial Board.
Remy Peptides Editorial Team
Editorial Board and editorial review for GLP-1, triple-agonist, supplier-verification, and regulatory-status pages that require evidence alignment across the trust cluster.
- Reference pages and research articles are reviewed against the same citation and compliance standard.
- Batch-evidence claims must match the current published batch record before publication or refresh.
- Readers can trace oversight through the editorial team page, the brand facts page, and the research standards page.
Corrections
- Minor (typos, broken links): fixed on discovery.
- Factual (data, regulatory status, attribution): corrected within 48 hours and logged in the article’s Update History or change note.
- Significant revisions (new data that changes conclusions): full editorial re-review with documented Update History and refreshed citations.
We do not silently alter published claims. Report errors to info@remypeptides.com or via the contact page; we review correction requests within 48 hours and preserve material claim changes in public page history.
Independence
Remy Peptides does not sell, supply, or broker any compound covered in this library. There is no commercial interest in any outcome reported here, and no pharmaceutical company or advertiser has editorial influence.
Compliance Guardrails
All content is written under a For Research Use Only standard. We do not publish treatment claims, diagnostic claims, dosing instructions for human use, or efficacy promises. Regulatory language is framed as status, evidence, observed outcomes, tolerability, and protocol context.
Update Signals
We refresh a page when a primary trial readout posts, a regulator changes status, a citation breaks, a published specification changes, or a reader flags a factual issue. Each refresh checks the title, meta description, structured data, visible citations, and internal links so the page copy and metadata stay aligned.